MGTX MeiraGTx Holdings plc

15.42
+0.28  (+2%)
Previous Close 15.14
Open 15.23
Price To Book 3.12
Market Cap 576,128,455
Shares 37,362,416
Volume 55,988
Short Ratio
Av. Daily Volume 107,949
Stock charts supplied by TradingView

NewsSee all news

  1. MeiraGTx Reports First Quarter 2020 Financial Results

    LONDON and NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended

  2. MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference

    LONDON and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and

  3. ALEXANDRIA REAL ESTATE EQUITIES, INC. (FormDEF 14A)

  4. MeiraGTx Reports Full Year 2019 Financial Results

    LONDON and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the full year ended

  5. MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

    PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGRAAV-RPGR is the only XLRP treatment in development to be awarded PRIME designation LONDON and NEW YORK, March 02, 2020

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 initial data due 2H 2020.
AAV-AQP1
Xerostomia
Data presented at AAO October 12, 2019.
AAV-RPE65
RPE65-Deficiency
Phase 1/2 data due 2020.
AAV-RPGR
X-Linked Retinitis Pigmentosa
Phase 1/2 trial initiation announced August 7, 2019.
AAV-CNGA3
Achromatopsia
Phase 1/2 trial ongoing.
AAV-CNGB3
Achromatopsia
Phase 1/2 presentation at ASCO May 29, 2020.
MGC018 (ASCO)
Solid Tumors

Latest News

  1. MeiraGTx Reports First Quarter 2020 Financial Results

    LONDON and NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended

  2. MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference

    LONDON and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and

  3. ALEXANDRIA REAL ESTATE EQUITIES, INC. (FormDEF 14A)

  4. MeiraGTx Reports Full Year 2019 Financial Results

    LONDON and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the full year ended

  5. MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

    PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGRAAV-RPGR is the only XLRP treatment in development to be awarded PRIME designation LONDON and NEW YORK, March 02, 2020

  6. MeiraGTx to Present at Upcoming Investor Conferences

    LONDON and NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and

  7. MeiraGTx to Host Parkinson's Disease R&D Day in New York

    LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson's disease-focused

  8. MeiraGTx to Present at Upcoming Healthcare Conferences

    LONDON and NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and

  9. Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019."Following the

  10. MeiraGTx Reports Third Quarter 2019 Financial Results

    LONDON and NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended

  11. MeiraGTx to Present at Upcoming Scientific and Investor Conferences

    LONDON and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present at the following

  12. MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences

    LONDON and NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company's